Sodium benzoate is a low-potency DAAO inhibitor that requires relatively high doses to achieve sufficient DAAO enzyme occupancy.48,49 In human trials, the first small RCT (n = 52) to study the potential efficacy of sodium benzoate as an adjunctive treatment in people with schizophrenia reported improved negative symptoms and neurocognition,50 but 3 subsequent sodium benzoate studies in specific patient populations showed mixed results in improving schizophrenia symptomatology. Here, DAO is linked to schizophrenia.